Skip to Main Content U.S. Department of Energy
small banner

Development of Antibody Microarrays for the National Cancer Institute Early Detection Research Network

Karin Rodland, Principal Investigator

Funding Agency: National Institutes of Health, National Cancer Institute

Antibody microarrays using single-chain antibody technology and a biotin tag for fluorescence detection.
Antibody microarrays using PNNL's single-chain antibody technology and a biotin tag for fluorescence detection were used to capture prostate specific antigen (PSA), a marker for prostate cancer that is detectable in blood. (B) Spot fluorescence for these assays is measured in triplicate. (C) Panel C shows an example of a standard curve for PSA generated using custom scFv antibodies and the custom software, ProMAT; both custom tools were developed at PNNL. Click for a larger version.

Collaborations among investigators at Pacific Northwest National Laboratory (PNNL) and members of the National Cancer Institute Early Detection Research Network (EDRN) are developing antibody microarrays capable of simultaneously assaying up to 50 distinct cancer biomarkers in a single test.  A biomarker reflects the state of a biological system, and particular biomarkers may be used to determine an organism’s disease state, disease susceptibility, or pathogen exposure.  The focus of the PNNL and EDRN collaboration is early cancer detection and cancer risk assessment.

This project uses PNNL's single-chain antibody library and proteomics capability as well as our researchers' expertise in cancer biology.  PNNL researchers are developing optimized antibodies directed against biomarkers identified by EDRN Biomarker Development collaborators across the country.  These antibodies will be used to produce and distribute 1500 microarray chips for clinical validation by EDRN Biomarker Reference Laboratories.

Systems Biology at PNNL

Research & Capabilities

Resources

Related Projects

Biomolecular Systems Initiative, image